Blood biomarkers to improve diagnosis and management of mild traumatic Brain injury in vulnerable patients.

Fonte Standard Gras
Identifiant

Unité de recherche

SEFRI

Numéro de projet

23.00484

Titre du projet

Blood biomarkers to improve diagnosis and management of mild traumatic Brain injury in vulnerable patients.

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Résumé des résultats (Abstract) (Anglais)	Cranial Computed Tomography (CCT), the current standard method to identify intracerebral lesions, is overused in case of mild traumatic brain injury (mTBI). This results in avoidable waiting time in the emergency department (ED), risks of radiation exposure for patients and to a waste of ED resources use and costs. Blood biomarkers of brain injury may correlate with imaging abnormalities and cognitive outcome. In this context, we are conducting a large clinical study (BRAINI) with mTBI adult patients to explore the performance of an automated assay measuring two promising blood biomarkers, GFAP and UCH-L1. BRAINI2 will focus on two poorly explored mTBI populations: the elderly where falls and pre-injury medications with anticoagulant drugs are common, and paediatrics where biomarkers data are very limited. BRAINI2 will establish an age-specific algorithm with objective mTBI diagnostic and prognostic indicators providing economical and health benefits.

Catégorie

Texte

Résumé des résultats (Abstract)
(Anglais)

Cranial Computed Tomography (CCT), the current standard method to identify intracerebral lesions, is overused in case of mild traumatic brain injury (mTBI). This results in avoidable waiting time in the emergency department (ED), risks of radiation exposure for patients and to a waste of ED resources use and costs. Blood biomarkers of brain injury may correlate with imaging abnormalities and cognitive outcome. In this context, we are conducting a large clinical study (BRAINI) with mTBI adult patients to explore the performance of an automated assay measuring two promising blood biomarkers, GFAP and UCH-L1. BRAINI2 will focus on two poorly explored mTBI populations: the elderly where falls and pre-injury medications with anticoagulant drugs are common, and paediatrics where biomarkers data are very limited. BRAINI2 will establish an age-specific algorithm with objective mTBI diagnostic and prognostic indicators providing economical and health benefits.